3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study von Camidge, D.R, Bazhenova, L.A, Salgia, R, Langer, C.J, Gold, K, Rosell, R, Shaw, A.T, Weiss, G.J, Dorer, D.J, Rivera, V.M, Conlan, M.G, Kerstein, D, Gettinger, S.N

Volltext

179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs... von Bardia, A., Lu, J., Kaklamani, V., Jung, J., Anderson-Villaluz, A.T., Conlan, M.G., Bidard, F-C., Cortés, J., Aftimos, P.G.

Volltext

343P - Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC) von Hamilton, E., Vidula, N., Ma, C., LoRusso, P., Bagley, R.G., Yu, Z., Annett, M., Weitzman, A., Conlan, M.G., Weise, A.

Volltext

Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC) von Hamilton, E., Vidula, N., Ma, C., LoRusso, P., Bagley, R.G., Yu, Z., Annett, M., Weitzman, A., Conlan, M.G., Weise, A.

Volltext

Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases von Kerstein, D., Gettinger, S., Gold, K., Langer, C.J., Shaw, A.T., Bazhenova, L.A., Salgia, R., Dorer, D.J., Conlan, M.G., Camidge, D.R.

Volltext

Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III sprint trial... von Vesole, D, Stadtmauer, E, Goodnough, L.T, Coutre, S, Howard, F, Lin, J.-S, Conlan, M.G

Volltext